anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Obstructive sleep apnea (OSA) is associated with behavioral, cognitive, metabolic and cardiovascular conditions. Continuous Positive Airway Pressure (CPAP) is the gold standard treatment for OSA. Despite being the most effective treatment for OSA, 46 to 83% of patients do not adhere to CPAP. New technologies for CPAP treatment have been developed in order to improve patient's comfort, adherence and effectiveness in reducing apnea, hypopneas and flow limitation events. As an example, the FLEX- PLUS technology which increases inspiratory positive pressure and decreases expiratory positive pressure would soften the rhythm of breathing. Sensawake is another technology which evaluates breathing pattern changes during CPAP therapy. When the breathing pattern suggests that patient is awake, a prompt relief in pressure is activated, like ramp feature. However, it is not clear whether CPAP FLEX- PLUS or Sensawake are superior compared with fixed pressure CPAP, in terms of polysomnographic parameters, especially flow limitation or adherence to treatment. Objective: To compare the effect of fixed pressure CPAP, CPAP FLEX- PLUS and Sensawake on sleep and compliance parameters in patients with moderate to severe OSA. Methods: Fifty male patients with moderate to severe OSA will be included in a crossover design study. All patients will use each CPAP modality for 30 days in a randomized order, namely CPAP with Fixed Pressure, Flex- PLUS and Sensawake. A week of washout period will be applied between treatments. All patients will wear the same nasal mask brand. At the end of each treatment (every 4 weeks), patients will undergo polysomnography and fill out Epworth, FOSQ, Pittsburgh questionnaires and a visual analogue scale assessing CPAP side effects and patient´s comfort. Finally, adherence to CPAP modalities will be systematically checked.
The invention discloses a preparation for treating dermatophytosis. The preparation mainly comprises the following components in parts by weight: 10-50 parts of a sophora angustifolia root extract;, 10-50 parts of a cortex pseudolaricis extract, 2-8 parts of triclosan and auxiliary materials. The preparation is prepared into a powder medicine or a spray. The powder medicine is obtained by the following steps: respectively grinding the sophora angustifolia root extract, the cortex pseudolaricis extract and triclosan into fine powder; then adding talcum powder which is 0.7-2 times the total amount of the medicine and pearl powder which is 0.7-2 times the total amount of the medicine; sieving with an 80-mesh sieve; then uniformly mixing, and subpackaging. The spray is obtained by the following steps: respectively grinding the sophora angustifolia root extract, the cortex pseudolaricis extract and triclosan into fine powder; sieving with the 80-mesh sieve; dissolving the fine powder in 60% ethanol; adding dimethyl sulfoxide which is 1.2% of the total amount of the spray, and fully stirring and mixing; filtering with a microfiltration membrane, and canning. The pharmaceutical formulation provided by the invention is respectively prepared into the powder medicine and the spray with dermatophytosis treatment effects, and meanwhile inhibits and kills fungi in shoes and on feet; due to double treatment effects, the curative effect is effectively improved, the treatment course is shortened, the dermatophytosis is unlikely to relapse after being healed, the preparation has high clinical use value.
PURPOSE:To obtain a powder cosmetic having excellent moisture retention effects, containing a metal salt of acid and/or a metal hydroxide, a water-soluble salt of alginic acid, an oil component and powder. CONSTITUTION:A cosmetic containing 1.0-30.0wt.% at least one selected from a bivalent-trivalent metal salt of acid (e.g. calcium lactate) and a bivalent- trivalent metal hydroxide (e.g. aluminum hydroxide), 3.0-30wt.% water-soluble salt of alginic acid, 3-20wt.% oil component and 50-95 wt. powder. The cosmetic is properly mixed with an antioxidant, an antiseptic, a perfume, an ultraviolet light absorber, etc., to give the objective substance. The substance is prepared into powder foundation, powder eye shadow, cheek rouge, face powder, eye liner, eyebrow, etc., and applied. This cosmetic has excellent spread, adhesivity, make-up effects and a moist feeling and a small change thereof with an elapse of time.
This is a randomized, double-blind, placebo-controlled, parallel-group, multicenter, dose-response study of patients who have a Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM IV) diagnosis of schizophrenia. The duration of the study is approximately 14 weeks, including a screening period of 1 week and a 13-week double-blind treatment period. Efficacy and safety will be evaluated periodically throughout the study. Samples for pharmacokinetic evaluation will be collected at designated time points, and a blood sample will be collected at baseline (before the start of double-blind treatment) for an optional pharmacogenomics (genetics) analysis. The hypothesis is that the 3 fixed doses of paliperidone are each more efficacious than placebo in treating subjects with schizophrenia. The effectiveness is measured primarily by the change in the Positive and Negative Syndrome Scale for Schizophrenia (PANSS), and secondarily, by the investigator's Clinical Global Impression of Severity (CGI-S) and by the investigator's evaluation of the patient on a Personal and Social Performance (PSP) Scale. Four injections of paliperidone palmitate 50, 100, or 150 milligrams equivalent administered in the gluteal muscle (buttocks). Injections will be given on Days 1, 8, 36, and 64 of the double-blind treatment period of the study.
AIM: To evaluate the outcomes of dynamic stabilization in the multilevel degenerative spondylotic spine, and to compare the two dynamic systems (Dynesys® and Orthrus®) to reveal the increasing role of dynamic systems in the management of the degenerative spine.
MATERIAL AND METHODS: A total of 74 patients who received dynamic stabilization for degenerative pathologies were retrospectively analyzed. Demographic details: preoperative data including neurological status, pain scores, and radiology; and intraoperative data including blood loss, duration of surgery, complications, and postoperative data including the neurologic status, duration of hospital stay, and pain scores were examined.
RESULTS: Patients in both groups showed statistically significant improvements in their Visual Analog Scale and Oswestry Disability Index scores. Significant corrections of thoracic kyphosis (T2-T12), the sagittal vertical axis, and T10-L2 thoracolumbar kyphosis were obtained in our cohort (p < 0.05). A total of 4 patients received revision surgery due to screw loosening. Patients were discharged after 3-4 days and mobilized on the first postoperative day.
CONCLUSION: We did not experience any serious issues in terms of stabilization in the cases in which we employed both systems. Our patients' clinical results were satisfactory in both systems. Existing systems can be used safely even in long-segment stabilization surgeries.
BACKGROUND AND AIMS: The potential impact of peripheral artery disease (PAD) on kidney outcomes is not well understood. The aim of this study was to explore the association between PAD and end-stage kidney disease (ESKD) and chronic kidney disease (CKD).
METHODS: Among 14,051 participants (mean age 54 [SD 6 years]) from the Atherosclerosis Risk in Communities study, we categorized PAD status as symptomatic PAD (intermittent claudication or leg revascularization), asymptomatic PAD (ankle-brachial index [ABI] ≤0.90 without clinical history of symptoms), and ABI 0.91-1.00, 1.01-1.10, 1.11-1.20 (reference), 1.21-1.30, and >1.30. We evaluated their associations with two kidney outcomes: ESKD (the need of renal replacement therapy or death due to kidney disease) and CKD (ESKD cases or an estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m2 with a ≥25 % decline from the baseline) using multivariable Cox proportional hazards models.
RESULTS: Over ∼30 years of follow-up, there were 598 cases of incident ESKD and 4686 cases of incident CKD. After adjusting for potential confounders, both symptomatic PAD and asymptomatic PAD conferred a significantly elevated risk of ESKD (hazard ratio 2.28 [95 % confidence interval 1.23-4.22] and 1.75 [1.19-2.57], respectively). Corresponding estimates for CKD were 1.54 (1.14-2.09) and 1.63 (1.38-1.93). Borderline low ABI 0.91-1.00 also showed elevated risk of adverse kidney outcomes after adjustment for demographic variables. Largely consistent results were observed across demographic and clinical subgroups.
CONCLUSIONS: Symptomatic PAD and asymptomatic PAD were independently associated with an elevated risk of ESKD and CKD. These results highlight the importance of monitoring kidney function in persons with PAD, even when symptoms are absent.
The present invention relates to crystals of phosphorylated Aurora-A kinase fragment alone and in complex with a ligand, amino acid residues 1-43 of human TPX2. This invention also relates to methods for designing and selecting ligands, in particular allosteric inhibitors of Aurora-A, that bind to the Aurora-A kinase and their use. Further, the present invention relates to certain indene and indole derivatives. The present invention relates to crystals of phosphorylated Aurora-A kinase alone and in complex with a ligand, amino acid residues 1-43 of human TPX2. This invention also relates to methods for designing and selecting ligands that bind to the Aurora-A kinase and their use. Further, the present invention relates to certain indene and indole derivative.
Many of the drugs used to treat cancer are metabolized by the CYP2C8 enzyme, the CYP3A4 enzyme, or both. The effect of concurrent administration of relacran and paclitaxel, a drug used to treat cancer, which are substrates for CYP2C8 and CYP3A4, is disclosed. The Relaconazole effectively inhibits CYP2C8 and CYP3A4 in an in vitro test, which shows that the in vivo paclitaxel plasma exposure can be increased by more than 5 times by simultaneously administering the Relaconazole and the paclitaxel, and the paclitaxel dosage needs to be obviously reduced when the paclitaxel and the Relaconazole are simultaneously administered. Surprisingly, paclitaxel plasma exposure was increased only by about 80%, rather than more than a 5-fold increase expected with administration of both relacran and paclitaxel. Applicants disclose a safe method of co-administration of relacran and paclitaxel by reducing the dose of paclitaxel to about half the dose when paclitaxel is administered alone. Relacran and such reduced doses of paclitaxel may be administered concurrently to treat cancer, such as ovarian or pancreatic cancer.
This study is a randomized, open-labelled trial. We randomly assigned patients within 24 hours after the onset of minor ischemic stroke or high-risk TIA to combination therapy with cilostazol and aspirin (aspirin 100mg with cilostazol 200 mg for 21 days) or to clopidogrel plus aspirin (aspirin 100mg with clopidogrel 75mg for 21 days). The primary outcome was stroke (ischemic or hemorrhagic) during 90 days of follow-up in an intention-to-treat analysis. The primary safety outcome was the moderate-to-severe bleeding event according to (GUSTO) definition. The secondary outcomes were new clinical vascular event (ischemic or hemorrhagic stroke, myocardial infarction, or vascular death), analyzed as a composite outcome and also as individual outcomes. Vascular death was defined as death due to stroke (ischemic or hemorrhagic), systemic hemorrhage, myocardial infarction, congestive heart failure, pulmonary embolism, sudden death, or arrhythmia.
A composition of substances generally comprises effective amounts of a mixture of a DMSO solution in a concentration ranging between 50%-100%, Oregano oil, Lavender oil, and Bay Leaf oil. Preferably, the effective amounts constitute −50% for DMSO, −20% for Oregano oil, −10% for Lavender oil, and −20% for Bay Leaf oil of the total weight of composition. The preferable concentration of DMSO solution is 100%. The DMSO solution constricts small capillaries and the dilating of medium size blood vessels. The composition is preferably usable for prevention of complications associated with second-degree thermal or chemical skin bums, for stopping the bleeding, for healing insect bites or Jelly fish stings, and for healing skin cuts and abrasions. A method for preparation of the composition comprises—mixing the effective amounts of Oregano oil, Lavender oil, and Bay Leaf oil, obtaining a mixture and—adding the effective amount of DMSO solution into the mixture.
People infected with human immunodeficiency virus (HIV), affected by their underlying diseases, are listed by the World Health Organization (WHO) as a high-risk population for SARS-CoV-2 infection.. More attention should be paid to personal protection and disease prevention. Vaccination of COVID-19 can effectively prevent COVID-19 virus infection and delay or prevent patients from developing into critical illness and reduce mortality. The safety and effectiveness of COVID-19 vaccine in this population were evaluated in order to play a scientific and theoretical supporting role in guiding COVID-19 vaccination more scientifically, reasonably and effectively. The samples of this study were collected and tested in the second affiliated Hospital of Chongqing Medical University. Patients with contraindications for vaccination will be excluded. The detected indexes included blood routine test, CD4, HIV virus load, COVID-19 antibody titer, antibody duration and other indexes of healthy people (control group) and HIV infenction people after vaccination ( 1, 3, 6 months after vaccination). The adverse reactions related to the vaccine were recorded.
The utility model discloses a multifunction physicotherapy granula, relating to a physical therapy apparatus which can be used in and outside human bodies. The physicotherapy granula comprises a magnet (1) and a sealing layer (2) sealing the magnet. The sealing layer (2) is provided with a medicine layer (3), or the medicine layer (3) is sleeved with a drug releasing layer (4) comprising two petals. Each petal is provided with 2-8 drug releasing holes (5), and the two petals are bitten or bonded together. Because of the achievement of medicine and magnetism combined treatment in and outside the bodies, the utility model has visible curative effect, and can treat and prevent various illnesses. The utility model can also be used to produce magnetic water, magnetic wine and magnetic vinegar.
Microcystin-LR (MC-LR), a cyanobacterial toxin, is a potent carcinogen implicated in colorectal cancer (CRC) progression. However, its impact on the tumor microenvironment (TME) during CRC development remains poorly understood. This study investigates the interaction between tumor cells and macrophages mediated by MC-LR within the TME and its influence on CRC progression. CRC mice exposed to MC-LR demonstrated a significant transformation from adenoma to adenocarcinoma. The infiltration of macrophages increased, and the IRE1α/XBP1 pathway was activated in CRC cells after MC-LR exposure, influencing macrophage M2 polarization under co-culture conditions. Additionally, hexokinase 2 (HK2), a downstream target of the IRE1α/XBP1 pathway, was identified, regulating glycolysis and lactate production. The MC-LR-induced IRE1α/XBP1/HK2 axis enhanced lactate production in CRC cells, promoting M2 macrophage polarization. Furthermore, co-culturing MC-LR-exposed CRC cells with macrophages, along with the IRE1α/XBP1 pathway inhibitor 4μ8C and the hexokinase inhibitor 2-DG, suppressed M2 macrophage-induced CRC cell migration, clonogenicity, and M2 macrophage polarization. This study elucidates the mechanism by which MC-LR-mediated interactions through the IRE1α/XBP1 pathway promote CRC progression, highlighting potential therapeutic targets.
Osteogenic bone implant compositions that approximate the chemical composition of natural bone are provided. The organic component of these implant compositions is osteoinductive despite the presence of the inorganic component and, further, is present in an amount sufficient to maximize the regenerative capabilities of the implant without compromising its formability and mechanical strength. The composition may be an osteoinductive powder, including demineralized bone matrix (DBM) particles, a calcium phosphate powder, and, optionally, a biocompatible cohesiveness agent. The powder may be combined with a physiologically- acceptable fluid to produce a formable, osteoinductive paste that self- hardens to form a poorly crystalline apatitic (PCA) calcium phosphate having significant compressive strength. The bone implant materials retain their cohesiveness when introduced at an implant site and are remodeled into bone in vivo. Methods for using these implant materials to repair damaged bone and a method of assaying the content of DBM particles, by weight, in a bone implant material are also provided.
The invention discloses a traditional Chinese medicine patch for treating osteoproliferation. According to traditional Chinese medicine, oldness, weakness, liver and kidney depletion, qi stagnation and blood stasis are inner causes of osteoproliferation, wind-cold-wetness evil invasion and trauma strain are the main outer causes of osteoproliferation, and therefore sclerotin generates loading type inflammatory inflammatory changes, qi and blood loss, blood stasis and stagnation and unsmooth main and collateral channels are caused, and osteoproliferation is caused. The patch is prepared from traditional Chinese medicine including crataeva leaves, Indian kalimeris herb, Laurocerasus zippeliana (Miq.) Yu et Lu, Kalopanax septemlobus (Thunb.) Koidz. roots, Osmanthus delavayi Franch., radix semiaquilegiae, Franchet Groundcherry, Drosera burmanni Vahl, Smilax stans Maxim., Gnetum montanum Markgr., Salix hypoleuca and Aralia echinocaulis Hand.- Mazz.. It is proved through clinical tests that the total effective rate is 98.0% and is obviously superior to the total effective rate of 70.0% of the contrast group.
Masitinib is a selective, oral tyrosine kinase inhibitor with neuroprotective capability demonstrated via numerous preclinical studies. Two of masitinib's main cellular targets are the mast cell and microglia cell. It is well-established that mast cells play a prominent role in neuroinflammatory processes. Microglia, resident immune cells of the central nervous system (CNS), also constitute an important source of neuroinflammatory mediators and may have fundamental roles in numerous neurodegenerative disorders. The development of masitinib in ALS is therefore based on the pharmacological action of masitinib in microglia cells and mast cells, thereby slowing microglial-related disease progression, reducing neuro-inflammation, and modulating the neuronal microenvironment in both central and peripheral nervous systems. This is a multicenter, double-blind, randomized, placebo-controlled, parallel-group (two ascending dose titrations of masitinib and matching placebo), comparative study of oral masitinib in the treatment of patients with amyotrophic lateral sclerosis (ALS).
Depression is a serious illness that affects a person's mood, thoughts, and physical being. Common symptoms of depression include persistent feelings of anxiety, guilt, or hopelessness; irregular sleep and appetite patterns; lethargy; disinterest in previously enjoyed activities; excessive irritability and restlessness; suicidal thoughts; and inability to concentrate. Depression is highly comorbid, often occurring in the presence of one or more other disorders. Up to 15% to 20% of the time, people with diabetes are also depressed. Diabetes is a disease that interferes with the body's proper production and use of the hormone insulin, which is needed to convert food into the energy required to perform daily life activities. Self-care is a crucial component of diabetes treatment. However, symptoms of depression can interfere with behaviors necessary to carry out this care. Cognitive behavioral therapy (CBT) has shown success in treating people with depression, but the effect of CBT on self-care behaviors and depression of those with diabetes is not well known. This study will evaluate the effectiveness of CBT for medical adherence and depression (CBT-AD) in people with a depressive mood disorder and type 2 diabetes.

Upon study entry, all participants will complete various assessments, including a psychiatric diagnostic interview, a series of paper questionnaires, neuropsychological testing, blood sample analysis, and blood sugar monitoring. Next, all participants will meet with a nutritionist and a nurse diabetes educator. The nutritionist will help set goals for eating, physical activity, weight, and blood glucose. The nurse diabetes educator will review diabetes medication history and blood glucose self-monitoring equipment.

Participants will then be randomly placed in one of two counseling groups. One group will meet for a single session that will be devoted to diabetes medical adherence. The other group will attend 10 to12 individual CBT sessions for diabetes medical adherence and depression management. The CBT sessions will last 45 to 50 minutes and will require practice of coping skills outside the sessions. Participants receiving CBT will also complete weekly assessments of depression, self-care, and diabetes medical adherence. All participants will be asked to monitor a prescribed medication with a pill cap for the course of the study. At Month 2, participants in both groups will also meet again with the nutritionist to review original goals and adjust them as necessary. Most of the previous study assessments will be repeated at Months 4, 8, and 12. The neuropsychological testing will be repeated only at Month 12.